Aclaris Therapeutics (ACRS) Competitors $2.72 -0.05 (-1.81%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACRS vs. IMTX, QURE, REPL, ETNB, PLRX, RLAY, AVXL, IMNM, KURA, and KROSShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Immatics (IMTX), uniQure (QURE), Replimune Group (REPL), 89bio (ETNB), Pliant Therapeutics (PLRX), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), Immunome (IMNM), Kura Oncology (KURA), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Immatics uniQure Replimune Group 89bio Pliant Therapeutics Relay Therapeutics Anavex Life Sciences Immunome Kura Oncology Keros Therapeutics Aclaris Therapeutics (NASDAQ:ACRS) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability. Does the media favor ACRS or IMTX? In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 3 articles in the media. Aclaris Therapeutics' average media sentiment score of 0.82 beat Immatics' score of 0.22 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community prefer ACRS or IMTX? Aclaris Therapeutics received 353 more outperform votes than Immatics when rated by MarketBeat users. However, 75.00% of users gave Immatics an outperform vote while only 66.61% of users gave Aclaris Therapeutics an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes38366.61% Underperform Votes19233.39% ImmaticsOutperform Votes3075.00% Underperform Votes1025.00% Do institutionals & insiders have more ownership in ACRS or IMTX? 98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ACRS or IMTX? Aclaris Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Which has better earnings & valuation, ACRS or IMTX? Aclaris Therapeutics has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$27.08M7.18-$88.48M-$0.52-5.23Immatics$115.50M7.08-$104.98M-$0.66-10.38 Is ACRS or IMTX more profitable? Immatics has a net margin of -47.94% compared to Aclaris Therapeutics' net margin of -136.65%. Immatics' return on equity of -15.90% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% Immatics -47.94%-15.90%-9.38% Do analysts prefer ACRS or IMTX? Aclaris Therapeutics currently has a consensus target price of $8.80, suggesting a potential upside of 223.53%. Immatics has a consensus target price of $16.67, suggesting a potential upside of 143.31%. Given Aclaris Therapeutics' higher probable upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than Immatics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryAclaris Therapeutics beats Immatics on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.29M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-5.2310.4289.5817.17Price / Sales7.18195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book1.235.094.774.78Net Income-$88.48M$151.83M$120.15M$225.60M7 Day Performance-15.53%-2.13%-1.92%-1.23%1 Month Performance-37.04%-3.10%11.47%3.36%1 Year Performance169.31%11.54%30.54%16.60% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics3.8513 of 5 stars$2.72-1.8%$8.80+223.5%+190.9%$194.29M$27.08M-5.2386IMTXImmatics1.4116 of 5 stars$7.31+1.4%$16.67+128.0%-25.3%$872.49M$115.50M-10.92260QUREuniQure3.5116 of 5 stars$17.56+14.0%$32.13+82.9%+172.3%$855.93M$28.59M-3.36500Analyst ForecastREPLReplimune Group4.5424 of 5 stars$12.29-2.1%$17.29+40.6%+67.4%$840.88MN/A-4.11210Insider TradeETNB89bio1.7833 of 5 stars$7.87+2.3%$30.33+285.4%-22.4%$835.21MN/A-2.6440News CoveragePositive NewsPLRXPliant Therapeutics3.3658 of 5 stars$13.69+2.9%$40.50+195.8%-19.0%$833.04M$1.58M0.0090RLAYRelay Therapeutics2.2525 of 5 stars$4.86+3.2%$20.50+321.8%-60.4%$813.47M$25.55M-1.80304Insider TradeAVXLAnavex Life Sciences3.3412 of 5 stars$9.33+10.3%$43.00+360.9%-2.5%$791.18MN/A-18.3640IMNMImmunome2.561 of 5 stars$12.48-0.8%$28.83+131.0%+33.0%$778.96M$10.13M-1.5540Positive NewsKURAKura Oncology4.4841 of 5 stars$9.92+3.0%$29.38+196.1%-27.0%$771.38MN/A-4.08142KROSKeros Therapeutics3.2934 of 5 stars$18.73-0.5%$81.33+334.2%-49.6%$758.70M$651,000.00-3.61100Gap DownHigh Trading Volume Related Companies and Tools Related Companies Immatics Competitors uniQure Competitors Replimune Group Competitors 89bio Competitors Pliant Therapeutics Competitors Relay Therapeutics Competitors Anavex Life Sciences Competitors Immunome Competitors Kura Oncology Competitors Keros Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACRS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
